{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:06:05Z","timestamp":1786118765646,"version":"build-2736575974"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/aci.0b013e328216f54a","type":"journal-article","created":{"date-parts":[[2007,7,9]],"date-time":"2007-07-09T04:07:31Z","timestamp":1183954051000},"page":"304-309","source":"Crossref","is-referenced-by-count":27,"title":["Severe cutaneous adverse reactions to drugs"],"prefix":"10.1097","volume":"7","author":[{"given":"Faith L","family":"Chia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khai Pang","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1365-2133.2003.05584.x","article-title":"A 6-month prospective survey of cutaneous drug reactions in a hospital setting","volume":"149","author":"Fiszenson-Albala","year":"2003","journal-title":"Br J Dermatol"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2230.2006.02185.x","article-title":"Epidemiological study of severe cutaneous adverse drug reactions in a city district of China","volume":"31","author":"Li","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"R4-4-20210128","first-page":"2234","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal anti-inflammatory drugs: a multinational perspective","volume":"30","author":"Mockenhaupt","year":"2003","journal-title":"J Rheumatol"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2165\/00002018-200629080-00005","article-title":"Serious skin reactions and selective COX-2 inhibitors. A case series from prescription-event monitoring In England","volume":"29","author":"Layton","year":"2006","journal-title":"Drug Safety"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.tox.2004.12.036","article-title":"Symptoms and dangers signs in drug hypersensitivity","volume":"209","author":"Bircher","year":"2005","journal-title":"Toxicol"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/14622416.7.6.813","article-title":"HLA-B locus in Caucasian patients with carbamazepine hypersensitivity","volume":"7","author":"Alfirevic","year":"2006","journal-title":"Pharmacogenomics"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome\u2026: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ajo.2006.09.029","article-title":"Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese","volume":"143","author":"Ueta","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/504874","article-title":"Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort Study","volume":"43","author":"Rauch","year":"2006","journal-title":"CID"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2332\/allergolint.55.27","article-title":"Immune mechanisms in drug allergy","volume":"55","author":"Roujeau","year":"2006","journal-title":"Allergol Int"},{"key":"R17-4-20210128","first-page":"769","article-title":"Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation","volume":"73","author":"Meth","year":"2006","journal-title":"Mt Sinai J Med"},{"issue":"1","key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0091-6749(00)90191-X","article-title":"Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response","volume":"105","author":"Leyva","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","article-title":"Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"155","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2004.04.034","article-title":"Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions","volume":"114","author":"Tapia","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaci.2006.07.013","article-title":"Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to \u03b2-lactams","volume":"118","author":"Rodriguez-Pena","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: A severity of illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archderm.140.7.890","article-title":"Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States","volume":"140","author":"Trent","year":"2004","journal-title":"Arch Derm"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Gu\u00e9gan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens Johnson syndrome; does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.burns.2006.04.031","article-title":"Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis","volume":"33","author":"Paquet","year":"2007","journal-title":"Burns"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicentre review of toxic epidermal necrolysis treatment in US burns centres at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clindermatol.2004.06.012","article-title":"Life-threatening acute adverse cutaneous drug reactions","volume":"23","author":"Wolf","year":"2005","journal-title":"Clinics in Dermatol"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000083947","article-title":"Novel treatments for drug induced toxic epidermal necrolysis","volume":"136","author":"Paquet","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1081-1206(10)62065-0","article-title":"Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin","volume":"91","author":"Mayorga","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R37-4-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulin: multicentre retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2332\/allergolint.55.9","article-title":"Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding","volume":"55","author":"French","year":"2006","journal-title":"Allergol Int"},{"key":"R39-4-20210128","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1081-1206(10)60789-2","article-title":"Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"97","author":"Khalili","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R40-4-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin for Stevens Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparitive study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"R41-4-20210128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"R42-4-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"R43-4-20210128","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2230.2005.01863.x","article-title":"The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"30","author":"Yeung","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"R44-4-20210128","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1542\/peds.112.6.1430","article-title":"Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: Seven cases and review of the literature","volume":"112","author":"Metry","year":"2003","journal-title":"Pediatrics"},{"key":"R45-4-20210128","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R46-4-20210128","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide vs placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"R47-4-20210128","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-\u03b1 antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"R48-4-20210128","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"R49-4-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporine A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J Trauma"},{"key":"R50-4-20210128","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2133.1997.tb02175.x","article-title":"Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine","volume":"136","author":"Redondo","year":"1997","journal-title":"Br J Dermatol"},{"key":"R51-4-20210128","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1067\/mjd.2002.118557","article-title":"Toxic epidermal necrolysis treated with N-acetylcysteine","volume":"46","author":"Velez","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R52-4-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejim.2004.04.007","article-title":"Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine","volume":"15","author":"Claes","year":"2004","journal-title":"Eur J Intern Med"},{"key":"R53-4-20210128","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1046\/j.1365-2133.2001.04428.x","article-title":"Angio-oedema caused by high doses of N-acetylcysteine in patients with anticonvulsant hypersensitivity syndrome","volume":"145","author":"Tas","year":"2001","journal-title":"Br J Dermatol"},{"key":"R54-4-20210128","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/00042560-199812150-00009","article-title":"A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pnuemocystis carinii pneumonia prophylaxis (CTN 057) Canadian HIV trials Network 057 Study Group","volume":"19","author":"Walmsley","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R55-4-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/ICO.0b013e31802eb264","article-title":"Erythema multiforme, Stevens-Johnson syndrome and Toxic epidermal necrolysis. Acute ocular manifestations, causes and management","volume":"26","author":"Chang","year":"2007","journal-title":"Corneal"},{"key":"R56-4-20210128","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","article-title":"Analysis of the acute ophthalmic manifestations of erythema multiforme\/Stevens-Johnson syndrome\/Toxic epidermal necrolysis disease spectrum","volume":"102","author":"Power","year":"1995","journal-title":"Ophthalmology"},{"key":"R58-4-20210128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ajo.2006.07.050","article-title":"A comparison between cultivated and conventional limbal stem cell transplantation for Stevens-Johnson syndrome","volume":"143","author":"Ang","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R59-4-20210128","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R60-4-20210128","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1034\/j.1398-9995.2003.00279.x","article-title":"Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations","volume":"58","author":"Aberer","year":"2003","journal-title":"Allergy"},{"key":"R62-4-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1034\/j.1600-0536.2002.470302.x","article-title":"Tetrazepam drug sensitivity: usefulness of the patch test","volume":"47","author":"Pirker","year":"2002","journal-title":"Contact Dermatitis"}],"container-title":["Current Opinion in Allergy & Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ACI.0b013e328216f54a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:40:43Z","timestamp":1786034443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00130832-200708000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0b013e328216f54a","relation":{},"ISSN":["1528-4050"],"issn-type":[{"value":"1528-4050","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}